Daily Endocrinology Research Analysis
Analyzed 56 papers and selected 3 impactful papers.
Summary
Today’s top endocrinology papers span mechanistic and translational advances: oxytocin signaling in adipocytes is required for lactation-associated lipid mobilization, an optimized protocol reliably generates highly functional stem cell–derived human islets across multiple lines, and integrated serum proteomics–liver transcriptomics reveals concordant biomarkers and pathways in MASLD progression. Collectively, they link hormone signaling, cell therapy readiness, and proteogenomic disease mechanisms.
Research Themes
- Hormonal control of lipid mobilization during lactation
- Scalable generation of functional human islets for diabetes cell therapy
- Proteogenomic biomarkers and mechanisms in MASLD progression
Selected Articles
1. Oxytocin signaling in adipocytes is required for normal milk fat production.
Using adipocyte-specific OXTR knockout dams, the study shows that oxytocin signaling in adipocytes is necessary to mobilize lipids and provide milk triglycerides that sustain neonatal growth. The work identifies adipose lipolysis as a key effector pathway for oxytocin during lactation, shifting focus beyond mammary epithelial synthesis.
Impact: This study uncovers a previously unappreciated endocrine circuit linking oxytocin to adipose lipolysis for milk fat provision, redefining hormonal control of lactation. It opens avenues for addressing lactation failure and neonatal nutrition via adipose-targeted strategies.
Clinical Implications: While preclinical, the findings suggest that impaired oxytocin–adipose signaling could contribute to low milk fat and suboptimal neonatal growth; assessing maternal oxytocin pathways and adipose lipolysis may aid evaluation of lactation insufficiency. Therapeutic modulation of lipolysis or OXT signaling warrants exploration.
Key Findings
- Adipocyte-specific deletion of OXTR in dams impairs lipid mobilization required for milk triglyceride supply.
- Oxytocin’s lactational role extends beyond mammary epithelial de novo lipogenesis to include adipose tissue lipolysis.
- Neonatal growth depends on oxytocin-driven adipose lipolysis in the dam.
Methodological Strengths
- Genetic, cell type–specific receptor deletion isolates adipocyte oxytocin signaling in vivo.
- Physiologically relevant endpoints (milk triglycerides and neonatal growth) strengthen translational inference.
Limitations
- Findings are from mouse models; human generalizability remains to be established.
- The abstract does not detail dose–response or downstream signaling mediators beyond lipolysis.
Future Directions: Define downstream adipocyte pathways mediating oxytocin-driven lipolysis, assess biomarkers of OXT–adipose signaling in human lactation disorders, and test therapeutic modulation in translational models.
Milk triglycerides, a crucial nutrient source for newborn mammals, can be derived from adipose lipolysis, dietary sources, or de novo synthesis in mammary epithelial cells (MECs). Here, we identify a critical role for the neuropeptide oxytocin (OXT) in providing milk triglyceride needed to sustain neonatal growth, mediated by its actions on adipose lipolysis. Dams lacking OXT receptors (OXTRs) specifically in adipocytes (Oxtr
2. An optimized protocol for efficient derivation of pancreatic islets from multiple human pluripotent stem cell lines.
A robust differentiation workflow across eight hPSC lines shortens the pancreatic progenitor stage, promotes endocrine progenitor self-aggregation to eliminate non-endocrine cells, and yields glucose-responsive SC-islets. Transplanted SC-islets mature further in vivo and normalize glycemia, with single-cell analyses confirming the absence of contaminating non-endocrine cells.
Impact: This protocol addresses a central bottleneck for T1D cell therapy by reliably generating highly functional, contamination-free SC-islets across diverse hPSC backgrounds. It provides a standardized, scalable pathway toward clinical-grade islet manufacturing.
Clinical Implications: Enables more consistent production of transplant-ready SC-islets; supports translational programs moving toward GMP-compliant manufacturing and clinical trials in T1D.
Key Findings
- Optimized timing (shortened PP stage) and 2D laminin-521 culture improve progression to endocrine progenitors.
- Self-aggregation of EP cells efficiently depletes proliferative and non-endocrine contaminants.
- Resulting SC-islets are glucose-responsive in vitro and restore normoglycemia after transplantation, with scRNA-seq confirming lack of non-endocrine cells.
Methodological Strengths
- Demonstrated robustness across eight independent hPSC lines.
- Functional in vivo validation with glycemic normalization and single-cell confirmation of cellular composition.
Limitations
- Preclinical study; long-term safety, durability, and immunogenicity not established.
- Transplantation site (anterior chamber of the eye) differs from clinical sites and may affect maturation kinetics.
Future Directions: Scale-up under GMP, evaluate encapsulation/immunoprotection strategies, compare clinical transplantation sites, and assess long-term function and safety in large animals.
The success of cell therapy for type 1 diabetes (T1D) depends on reliable differentiation of stem cells into functional pancreatic islets. Current protocols produce stem cell-derived islets (SC-islets) that contain non-endocrine cells and show limited maturity. We developed a robust protocol that generates functional SC-islets from all eight tested human pluripotent stem cell (hPSC) lines. Differentiation to the endocrine progenitor (EP) stage on 2D laminin-521 is improved by shortening the prior pancreatic progenitor (PP) stage. Notably, allowing EP cells to self-aggregate efficiently removes proliferative and non-endocrine cells. Subsequent suspension culture yields SC-islets with strong glucose responsiveness in vitro. After transplantation into the anterior chamber of the eye of diabetic mice, SC-islets further mature and restore normal glycemic control. Single-cell analyses show that the SC-islets are free of non-endocrine cell populations before and after transplantation. This protocol enables production of highly functional SC-islets suitable for T1D cell therapy.
3. Integrated serum proteomic and liver genomic analyses identify molecular signatures associated with metabolic dysfunction-associated steatotic liver disease: a multi-cohort study.
Across >4,000 participants spanning cross-sectional MRI and a 9.8-year prospective cohort plus transcriptomic cohorts, specific serum proteins (e.g., C3, C9, APOF, SHBG) tracked MASL risk and mapped to intrahepatic transcriptional changes implicating complement dysregulation and extracellular vesicle pathways in MASH and fibrosis. Findings provide concordant non-invasive biomarkers and mechanistic targets.
Impact: By integrating population-scale proteomics with liver transcriptomics and validating across independent cohorts, this study bridges systemic biomarkers to hepatic pathobiology in MASLD, enabling earlier risk stratification and target nomination.
Clinical Implications: Candidate serum proteins (e.g., SHBG, APOF, complement components) could inform non-invasive panels for early MASLD/MASH risk and fibrosis staging; complement- and vesicle-related pathways suggest therapeutic angles.
Key Findings
- Serum C3, C9, F9, VTN, AFM, APOD, APOF, and SHBG associated with MASL risk in MRI-based and prospective GNHS cohorts.
- Liver transcriptomics showed downregulation of complement-related genes (C9, C4BPB, C1RL, APOF, ITIH4) in high NAS, implicating complement dysregulation.
- Fibrosis associations (SHBG, A2M, GSN, C7, LUM, IGHG3, IGFALS) and extracellular vesicle pathways were identified and validated in Japanese and German cohorts.
Methodological Strengths
- Multi-cohort design with both cross-sectional and prospective components and independent international validation.
- Integrated multi-omics linking serum proteomics to liver transcriptomics enhances mechanistic inference.
Limitations
- Observational design cannot establish causality; multiple comparisons raise false discovery concerns despite reported P-values.
- Heterogeneity in imaging modalities and cohorts may influence effect estimates.
Future Directions: Prospective validation of biomarker panels, interventional studies targeting complement/vesicle pathways, and integration with clinical risk models to improve MASLD stratification.
BACKGROUND: Circulating proteomics acts as an intermediate phenotype linking genetic susceptibility to MASLD. However, current evidence rarely establishes a direct concordance between serum protein levels and hepatic gene expression. We aimed to perform a multi-cohort joint analysis of serum proteomics and transcriptomics to characterize essential molecular features for MASLD. METHODS: For the serum proteomic analysis of simple steatosis (MASL), we conducted a cross-sectional investigation in an MRI-based cohort (N/cases: 1048/428) and further examined the prospective association between protein features and MASL incidence (N/cases: 2945/1947) ascertained by ultrasonography over a median 9.8-year follow-up in the Guangzhou Nutrition and Health Study (GNHS) cohort. In parallel, we characterized fibrosis and MASH-related transcriptional features using liver transcriptomics from the MASH cohort (N = 94) and validated these gene signatures for MASH in liver transcriptomes from the independent Japanese and German populations (N = 98 and 59). RESULTS: The serum proteomic analysis identified the C3, C9, F9, VTN, AFM, APOD, APOF, and SHBG proteins were significantly associated with MASL risk (P < 0.05). Liver transcriptomic analysis revealed a coordinated downregulation of C9, C4BPB, C1RL, APOF, and ITIH4 in the high NAS group, implicating dysregulated complement activation as a critical mechanism driving disease progression. Furthermore, SHBG, A2M, GSN, C7, LUM, IGHG3, and IGFALS were associated with liver fibrosis stages, and pathways related to extracellular exosomes and vesicles were implicated in fibrotic development. Consistently, in the Japanese and Germany cohorts, APOF, GSN, and LUM exhibited aberrant expression in both MASH patients and those with high NAS scores. CONCLUSIONS: The multi-cohort study identified specific serum protein signatures associated with MASL risk, which correspond to dysregulated gene expression patterns in hepatocytes. These findings bridge the gap between systemic circulatory changes and intrahepatic pathological progression, providing not only robust non-invasive biomarkers for early stratification but also potential mechanistically-driven therapeutic targets for halting the progression of MASLD.